FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

١	Was	hing	ton,	D.C.	20549	

wasnington, D.C. 20549	OMB APPRO)VAL
STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP	OMB Number:	3235-028

OMB Number: Estimated average burden hours per response: 0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b)

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

							•	•										
1. Name and Address of Reporting Person * $\underline{Cleveland\ Paul\ B}$					2. Issuer Name and Ticker or Trading Symbol SANGAMO BIOSCIENCES INC [SGMO]								Relationship of Reporting Person(s) to Issuer (Check all applicable) X Director 10% Owner					
	NGAMO B	irst) IOSCIENCES II D TECH CNTR.		ANAL		3. Date of Earliest Transaction (Month/Day/Year) 01/15/2014									give title		Other (s	
BLVD				4. 1	4. If Amendment, Date of Original Filed (Month/Day/Year)								6. Individual or Joint/Group Filing (Check Applicable Line)					
(Street) RICHMOND CA 94804				-									X Form filed by One Reporting Person Form filed by More than One Reporting Person					
(City)	(S	tate)	(Zip)															
		Tab	le I - N	on-Deri	vative	Sec	uriti	ies Ac	quired	l, Di	sposed c	of, or Be	eneficia	ly Owne	d			
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/					Execution Date,				es Acquired (A) or Of (D) (Instr. 3, 4 a		Benefic Owned	ies ially Following	Form (D) or	: Direct r Indirect str. 4)	7. Nature of Indirect Beneficial Ownership			
									Code	v	Amount	(A) or (D)	Price	Reporte Transac (Instr. 3	ction(s)			(Instr. 4)
Common Stock 01/15/20					2014				М		8,333	A	\$5.03	8	,333		D	
Common	Stock			01/15/	2014				S ⁽¹⁾		8,333	D	\$18.684(2) 0			D		
		7	able II								posed of, converti			/ Owned				
1. Title of Derivative Security (Instr. 3) 2. Conversio or Exercis Price of Derivative Security		3. Transaction Date (Month/Day/Year)	Execution Date, if any		4. Transa Code (8)				6. Date Exercisable and Expiration Date (Month/Day/Year)			7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number derivative Securities Beneficial Owned Following Reported Transactio (Instr. 4)	is Silly	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
					Code	v	(A)	(D)	Date Exercisa	ıble	Expiration Date	Title	Amount or Number of Shares					
Stock Option (Right to	\$5.03	01/15/2014			M			8,333	(3)		06/20/2022	Common Stock	8,333	\$0.00	1,667	,	D	

Explanation of Responses:

- 1. The sales reported in this Form 4 were effected pursuant to the Rule 10b5-1 trading plan adopted by the Reporting Person on June 7, 2013.
- 2. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$18.36 to \$18.92, inclusive. The Reporting Person undertakes to provide to Sangamo BioSciences, Inc., any security holder of Sangamo BioSciences, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within such range.
- 3. All shares underlying this option are vested and immediately exercisable

Remarks:

/s/ Florence Tam, Attorney-in-01/17/2014 **Fact**

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.